PCPro:一种临床可及的循环脂质生物标志物特征用于预后不良的转移性前列腺癌
研究基于105例转移性去势抵抗性前列腺癌(mCRPC)男性发现队列,开发符合监管要求的液相色谱-质谱候选脂质检测,构建多种风险评分Cox预后模型,选一致性指数最高者PCPro在183例独立验证队列验证。PCPro阳性者总生存显著短于阴性者,结论为PCPro可前瞻性识别预后不良的mCRPC男性,需前瞻性临床试验确定PCPro阳性者能否从靶向脂质代谢药物获益。
要点
- PCPro包含Cer(d18:1/18:0)、Cer(d18:1/24:0)、Cer(d18:1/24:1)、甘油三酯和总胆固醇。
- 发现队列中PCPro阳性者中位OS 12.0个月 vs 阴性者24.2个月,HR 3.75(95%CI 2.29-6.15),p<0.001。
- 验证队列中PCPro阳性者中位OS 13.0个月 vs 阴性者25.7个月,HR 2.13(95%CI 1.46-3.12),p<0.001。
核心结论
- 已开发PCPro脂质生物标志物检测,能够前瞻性识别预后不良的mCRPC男性。
- 需要前瞻性临床试验来确定PCPro阳性男性是否会从靶向脂质代谢的治疗药物中获益。
研究设计与样本
- 开发符合监管要求的候选脂质液相色谱-质谱检测,在105例mCRPC男性发现队列中测试。
- 使用发现队列构建多种总生存风险评分Cox回归预后模型,选择一致性指数最高的模型PCPro在183例独立验证队列中验证。
主要发现
- 在发现队列和验证队列中,PCPro阳性男性总生存显著短于PCPro阴性男性。
- 发现队列:PCPro阳性者中位OS 12.0个月 vs PCPro阴性者24.2个月,HR 3.75(95%CI 2.29-6.15),p<0.001。
- 验证队列:PCPro阳性者中位OS 13.0个月 vs PCPro阴性者25.7个月,HR 2.13(95%CI 1.46-3.12),p<0.001。
关键数值与推荐
- PCPro脂质生物标志物包含Cer(d18:1/18:0)、Cer(d18:1/24:0)、Cer(d18:1/24:1)、甘油三酯和总胆固醇。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要前瞻性临床试验来确定PCPro阳性男性是否会从靶向脂质代谢的治疗药物中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Using comprehensive plasma lipidomic profiling from men with metastatic castration-resistant prostate cancer (mCRPC), we have previously identified a poor-prognostic lipid profile associated with shorter overall survival (OS). In order to translate this biomarker into the clinic, these men must be identifiable via a clinically accessible, regulatory-compliant assay. METHODS: A single regulatory-compliant liquid chromatography-mass spectrometry assay of candidate lipids was developed and tested on a mCRPC Discovery cohort of 105 men. Various risk-score Cox regression prognostic models of OS were built using the Discovery cohort. The model with the highest concordance index (PCPro) was chosen for validation and tested on an independent Validation cohort of 183 men. RESULTS: PCPro, the lipid biomarker, contains Cer(d18:1/18:0), Cer(d18:1/24:0), Cer(d18:1/24:1), triglycerides and total cholesterol. Within the Discovery and Validation cohorts, men who were PCPro positive had significantly shorter OS compared to those who were PCPro negative (Discovery: median OS 12.0 months vs 24.2 months, hazard ratio (HR) 3.75 [95% confidence interval (CI) 2.29-6.15], p < 0.001, Validation: median OS 13.0 months vs 25.7 months, HR = 2.13 [95% CI 1.46-3.12], p < 0.001). CONCLUSIONS: We have developed PCPro, a lipid biomarker assay capable of prospectively identifying men with mCRPC with a poor prognosis. Prospective clinical trials are required to determine if men who are PCPro positive will benefit from therapeutic agents targeting lipid metabolism.
引用
- Scheinberg T, Lin HM, Fitzpatrick M, et al. PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2023. PMID: 37147359. doi:10.1038/s41391-023-00666-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。